1 day Ago By ABMN Staff
Renaissance Technologies LLC trimmed its position in shares of Allogene Therapeutics, Inc. ( NASDAQ:ALLO – Free Report ) by 13.6% during the fourth quarter, Holdings Channel.
com reports. The fund owned 554,541 shares of the company’s stock after selling 87,468 shares during the quarter. Renaissance Technologies LLC’s holdings in Allogene Therapeutics were worth $1,181,000 as of its most recent SEC filing.
Several other institutional investors have also recently made changes to their positions in the company. Barclays PLC boosted its holdings in Allogene Therapeutics by 101.5% during the third quarter.
Barclays PLC now owns 342,973 shares of the company’s stock worth $959,000 after purchasing an additional 172,745 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Allogene Therapeutics by 14.4% in the 3rd quarter.
Geode Capital Management LLC now owns 3,227,104 shares of the company’s stock worth $9,037,000 after buying an additional 407,070 shares during the last quarter. Nordea Investment Management AB grew its holdings in shares of Allogene Therapeutics by 2.1% in the fourth quarter.
Nordea Investment Management AB now owns 460,641 shares of the company’s stock valued at $986,000 after acquiring an additional 9,635 shares in the last quarter. abrdn plc purchased a new stake in shares of Allogene Therapeutics during the fourth quarter valued at approximately $776,000. Finally, Vontobel Holding Ltd.
lifted its holdings in Allogene Therapeutics by 788.4% during the fourth quarter. Vontobel Holding Ltd.
now owns 195,457 shares of the company’s stock worth $416,000 after acquiring an additional 173,457 shares during the period. Institutional investors own 83.63% of the company’s stock.
Wall Street Analysts Forecast Growth A number of research analysts have issued reports on ALLO shares. Citizens Jmp upgraded Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price objective for the company in a research note on Friday, March 14th.
Canaccord Genuity Group restated a “buy” rating and set a $14.00 price objective on shares of Allogene Therapeutics in a report on Friday, March 14th. Royal Bank of Canada reiterated an “outperform” rating and issued a $10.
00 target price on shares of Allogene Therapeutics in a research note on Friday, March 14th. Finally, HC Wainwright decreased their price target on shares of Allogene Therapeutics from $9.00 to $8.
00 and set a “buy” rating for the company in a research note on Wednesday, March 19th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $9.
29. Allogene Therapeutics Trading Down 1.9 % Shares of ALLO stock opened at $1.
54 on Wednesday. Allogene Therapeutics, Inc. has a 12 month low of $1.
23 and a 12 month high of $3.78. The stock has a market capitalization of $334.
59 million, a P/E ratio of -0.99 and a beta of 0.99.
The firm’s 50 day moving average is $1.67 and its 200 day moving average is $2.04.
Allogene Therapeutics ( NASDAQ:ALLO – Get Free Report ) last posted its quarterly earnings results on Thursday, March 13th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.
34) by $0.06. On average, equities analysts predict that Allogene Therapeutics, Inc.
will post -1.28 EPS for the current year. Insider Buying and Selling at Allogene Therapeutics In other Allogene Therapeutics news, insider Timothy L.
Moore sold 14,746 shares of the firm’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $1.71, for a total value of $25,215.
66. Following the completion of the transaction, the insider now directly owns 250,713 shares of the company’s stock, valued at $428,719.23.
This trade represents a 5.55 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link .
Also, CEO David D. Chang sold 46,668 shares of the company’s stock in a transaction on Friday, March 14th. The stock was sold at an average price of $1.
96, for a total transaction of $91,469.28. Following the completion of the transaction, the chief executive officer now directly owns 5,276,569 shares in the company, valued at approximately $10,342,075.
24. The trade was a 0.88 % decrease in their position.
The disclosure for this sale can be found here . Insiders sold 87,268 shares of company stock valued at $159,584 in the last quarter. 24.
30% of the stock is currently owned by corporate insiders. Allogene Therapeutics Company Profile ( Free Report ) Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).
See Also Want to see what other hedge funds are holding ALLO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allogene Therapeutics, Inc. ( NASDAQ:ALLO – Free Report ).
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
